| pubmed-article:15026797 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15026797 | lifeskim:mentions | umls-concept:C0205851 | lld:lifeskim |
| pubmed-article:15026797 | lifeskim:mentions | umls-concept:C0205070 | lld:lifeskim |
| pubmed-article:15026797 | lifeskim:mentions | umls-concept:C0405581 | lld:lifeskim |
| pubmed-article:15026797 | lifeskim:mentions | umls-concept:C1328050 | lld:lifeskim |
| pubmed-article:15026797 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:15026797 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:15026797 | pubmed:dateCreated | 2004-3-17 | lld:pubmed |
| pubmed-article:15026797 | pubmed:abstractText | High-dose regimes containing etoposide, carboplatin and an oxazaphospharine can salvage 30-40% of patients with relapsed or refractory male germ cell tumours (GCTs). The additional benefit of paclitaxel in such high-dose therapy has not been tested. Between March 1995 and November 2002, 36 male GCT patients were treated with Carbop-EC-T (paclitaxel 75 mg x m(-2), etoposide 450 mg x m(-2), carboplatin AUC 10 on days -7, -5 and -3 and cyclophosphamide 60 mg x kg(-1) on days -5 and -3) followed by peripheral blood stem cell infusion (day 0). The 1-year overall survival rate for all patients is 67% (median follow-up 29 months). For the 24 patients with cisplatin-sensitive disease, the 1-year overall and event-free survivals are 88 and 64%, respectively. For those with cisplatin refractory or absolutely refractory disease, the 1-year overall survival is 25%. In all, 12 patients relapsed at a median duration of 5 months, 11 of whom have died. There were also six treatment-related deaths, five associated with pneumonitis. Pulmonary toxicity has been reported with paclitaxel in other high-dose regimes. Since altering our protocol so that paclitaxel is infused over 24 h with steroid prophylaxis, only one of 18 patients (13 testicular GCTs and five other tumour types) has had a treatment-related death. Our results suggest that Carbop-EC-T may enable a greater proportion of patients with relapsed and refractory GCTs to enter long-term remission. | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15026797 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15026797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15026797 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15026797 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:15026797 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:15026797 | pubmed:author | pubmed-author:NewlandsE SES | lld:pubmed |
| pubmed-article:15026797 | pubmed:author | pubmed-author:HarlandS JSJ | lld:pubmed |
| pubmed-article:15026797 | pubmed:author | pubmed-author:HaynesRR | lld:pubmed |
| pubmed-article:15026797 | pubmed:author | pubmed-author:DriverDD | lld:pubmed |
| pubmed-article:15026797 | pubmed:author | pubmed-author:GilesCC | lld:pubmed |
| pubmed-article:15026797 | pubmed:author | pubmed-author:SecklM JMJ | lld:pubmed |
| pubmed-article:15026797 | pubmed:author | pubmed-author:KanferE JEJ | lld:pubmed |
| pubmed-article:15026797 | pubmed:author | pubmed-author:McNeishI AIA | lld:pubmed |
| pubmed-article:15026797 | pubmed:author | pubmed-author:RustinG J SGJ | lld:pubmed |
| pubmed-article:15026797 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15026797 | pubmed:day | 22 | lld:pubmed |
| pubmed-article:15026797 | pubmed:volume | 90 | lld:pubmed |
| pubmed-article:15026797 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15026797 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15026797 | pubmed:pagination | 1169-75 | lld:pubmed |
| pubmed-article:15026797 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:meshHeading | pubmed-meshheading:15026797... | lld:pubmed |
| pubmed-article:15026797 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15026797 | pubmed:articleTitle | Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours. | lld:pubmed |
| pubmed-article:15026797 | pubmed:affiliation | Department of Medical Oncology, Imperial College School of Medicine, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK. | lld:pubmed |
| pubmed-article:15026797 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15026797 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15026797 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15026797 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15026797 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15026797 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15026797 | lld:pubmed |
